U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Approval Year

Substance Class Protein
Created
by admin
on Mon Mar 31 21:57:14 GMT 2025
Edited
by admin
on Mon Mar 31 21:57:14 GMT 2025
Protein Sub Type
Sequence Type COMPLETE
Record UNII
6NP3XSMIP3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FLJ10847
Preferred Name English
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
Common Name English
MATE1
Common Name English
SOLUTE CARRIER FAMILY 47 MEMBER 1
Common Name English
SLC47A1
Common Name English
MGC64822
Common Name English
MATE-1
Common Name English
Classification Tree Code System Code
UCSF-FDA TRANSPORTAL SLC47A1
Created by admin on Mon Mar 31 21:57:14 GMT 2025 , Edited by admin on Mon Mar 31 21:57:14 GMT 2025
Code System Code Type Description
FDA UNII
6NP3XSMIP3
Created by admin on Mon Mar 31 21:57:14 GMT 2025 , Edited by admin on Mon Mar 31 21:57:14 GMT 2025
PRIMARY
Related Record Type Details
INHIBITOR -> TRANSPORTER
IC50
INHIBITOR -> TRANSPORTER
SUBSTRATE -> TRANSPORTER
INHIBITOR -> TRANSPORTER
Rifamycin is an inhibitor of renal transporters organic anion transporter (OAT) 3, multidrug and toxin extrusion (MATE) 1, and MATE2-K transporters in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose, clinically relevant inhibition of these transporters in vivo is unlikely.
INHIBITOR -> TRANSPORTER
TRANSPORTER -> INHIBITOR
SUBSTRATE -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
SUBSTRATE -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
IC50
INHIBITOR -> TRANSPORTER
SUBSTRATE -> TRANSPORTER
SUBSTRATE -> TRANSPORTER
SUBSTRATE -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> TRANSPORTER
IC50
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
SUBSTRATE -> TRANSPORTER
INHIBITOR -> METABOLIC ENZYME
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
IC50
SUBSTRATE -> TRANSPORTER
INHIBITOR -> TRANSPORTER
IN VITRO
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
REVERSIBLE
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
SUBSTRATE -> TRANSPORTER
INHIBITOR -> TRANSPORTER
TISSUE EXPRESSION->TRANSPORTER
INHIBITOR -> TRANSPORTER
WEAK
IC50
INHIBITOR -> TRANSPORTER
SUBSTRATE -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
SUBSTRATE -> TRANSPORTER
INHIBITOR -> TRANSPORTER
The results suggest that KLISYRI has no clinically meaningful effect on the PK of drugs mediated by MATE1
IC50
INHIBITOR -> TRANSPORTER
IC50
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
corrected for non-specific binding
IC50
SUBSTRATE -> TRANSPORTER
SUBSTRATE -> TRANSPORTER
SUBSTRATE -> TRANSPORTER
INHIBITOR -> TRANSPORTER
SUBSTRATE -> TRANSPORTER
INHIBITOR -> TRANSPORTER
Co?administration of BIKTARVY with dofetilide may increase dofetilide plasma concentrations which can lead to serious and/or life threatening events.
CLINICALLY SIGNIFICANT
IC50
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER
IC50
INHIBITOR -> TRANSPORTER
SUBSTRATE -> TRANSPORTER
INHIBITOR -> TRANSPORTER
INHIBITOR -> TRANSPORTER

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO_ACID_SUBSTITUTION [1_1] M N-ACETYLMETHIONINE 9J12WX5B6A
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL